IDH2 and astrocytoma (excluding glioblastoma): Survival benefits persisted across histologies, notably in molecular subgroups like IDH-mutant astrocytoma (HR, 0.38; P=0.013) and oligodendroglioma (HR, 0.21; P=0.029), despite limited sample sizes (21).